Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia

被引:26
|
作者
Recto, CS
Acosta, S
Dobs, A
机构
[1] Philippine Heart Ctr, Quezon City, Philippines
[2] Hosp San Jose, Serv Endocrinol, Bogota, Colombia
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
关键词
simvastatin; atorvastatin; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; hypercholesterolemia; low-density lipoprotein cholesterol; triglycerides;
D O I
10.1002/clc.4960230910
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Simvastatin and atorvastatin are effective statins for treating hypercholesterolemia. Hypothesis: The study was undertaken to compare the efficacy and tolerability of simvastatin 20 and 40 mg/day and atorvastatin 10 and 20 mg/day. Methods: In this multinational, open-label, crossover study, 258 patients with primary hypercholesterolemia were randomized after 4 weeks of diet plus placebo to once-daily administration of a starting dose sequence of simvastatin (20 mg) or atorvastatin (10 mg), or a higher dose sequence of simvastatin (40 mg) or atorvastatin (20 mg) for 6 weeks. Patients were then switched after a I-week washout to the corresponding starting or higher dose of the alternate drug for a second 6-week period. The primary endpoint was the mean percent change from baseline to Week 6 in low-density lipoprotein (LDL) cholesterol; percent changes from baseline in total cholesterol, high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B were also compared. Safety was assessed through adverse experiences and laboratory measurements. Results: Both statins produced statistically significant improvements in all measured plasma lipids and lipoproteins. The main treatment comparison showed no statistically significant difference in changes in LDL cholesterol and triglycerides, whereby the overall effects were comparable when doses of 20 mg and 40 mg of simvastatin were compared with atorvastatin 10 mg and 20 mg. The mean percent reductions for LDL cholesterol from baseline to Week 6 ranged from 35-42% for the entire study cohort. An LDL cholesterol level less than or equal to 130 mg/dl (3.4 mmol/l) was achieved in approximately 70% of patients treated with both drugs in this study. Simvastatin and atorvastatin were well tolerated at the doses studied. Conclusion: In patients with hypercholesterolemia, the most commonly used doses of simvastatin and atorvastatin produced similar changes in LDL cholesterol and achieved an LDL cholesterol level I 130 mg/dl (3.4 mmol/l) in a similar number of patients. Both statins were well tolerated.
引用
收藏
页码:682 / 688
页数:7
相关论文
共 50 条
  • [31] A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia
    Niman, Stephanie
    Rana, Khyatiben
    Reid, Jessica
    Sheikh-Ali, Mae
    Lewis, Todd
    Choksi, Rushab R.
    Goldfaden, Rebecca F.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (06) : 535 - 548
  • [32] A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia
    Stephanie Niman
    Khyatiben Rana
    Jessica Reid
    Mae Sheikh-Ali
    Todd Lewis
    Rushab R. Choksi
    Rebecca F. Goldfaden
    American Journal of Cardiovascular Drugs, 2020, 20 : 535 - 548
  • [33] Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy
    Palacios, R
    Santos, J
    González, M
    Ruiz, J
    Valdivielso, P
    Márquez, M
    González-Santos, P
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 30 (05) : 536 - 537
  • [34] SIMVASTATIN IN SEVERE PRIMARY HYPERCHOLESTEROLEMIA - EFFICACY, SAFETY, AND TOLERABILITY IN 595 PATIENTS OVER 18 WEEKS
    SIMONS, LA
    ABRAHAM, R
    BEILIN, L
    MASAREI, J
    BENG, C
    PANNALL, P
    CAIN, H
    BRADFIELD, R
    CALVERT, GD
    CORNISH, G
    ENGLAND, J
    CRAIG, IH
    HELLER, RF
    SMITH, AJ
    HUNT, D
    JANUS, ED
    BEST, JD
    LLOYD, B
    HUNG, J
    NEWNHAM, H
    BARTER, P
    SIMONS, LA
    SULLIVAN, D
    THOMAS, DW
    TALLIS, G
    WAHLQVIST, M
    WILCKEN, DE
    TURNER, G
    WILMSHURST, E
    CLIFTONBLIGH, P
    WOODHOUSE, S
    LEPRE, F
    CLINICAL CARDIOLOGY, 1993, 16 (04) : 317 - 322
  • [35] EFFICACY AND TOLERABILITY OF TWO DIFFERENT FORMULATIONS OF ATORVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA; MULTICENTER, PROSPECTIVE, RANDOMIZED TRIAL
    Kim, S. H.
    Lee, H. L.
    Kim, H. L.
    Seo, J. B.
    Chung, W. Y.
    Zo, J. H.
    Kim, M. A.
    An, K. J.
    CARDIOLOGY, 2014, 128 : 393 - 393
  • [36] Ezetimibe/Simvastatin Versus Atorvastatin in Metabolic Syndrome Patients with Hypercholesterolemia
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Grundy, Scott M.
    Hsueh, Willa
    Parving, Hans-Henrik
    Rosen, Jeffrey B.
    Adewale, Adeniyi J.
    Polis, Adam B.
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    DIABETES, 2009, 58 : A181 - A181
  • [37] Evaluation of Dose Efficacy of Treatment with Atorvastatin, Rosuvastatin And Simvastatin in Patients with Hyperlipidemia
    Demir, Orhan
    Sevimli, Serdar
    Degirmenci, Husnu
    Duman, Hakan
    Bakirci, Eftal Murat
    Demirelli, Selami
    Hamur, Hikmet
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : C182 - C182
  • [38] Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia
    Raal, FJ
    Pilcher, GJ
    Veller, MG
    Kotze, MJ
    Joffe, BI
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (11): : 1344 - +
  • [39] Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia
    Davidson, MH
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (02) : 398 - 399
  • [40] EFFICACY AND SAFETY OF SIMVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA
    YOMTOV, B
    CHATENETDUCHENE, L
    SEMAINE DES HOPITAUX, 1995, 71 (7-8): : 249 - 254